Inhaled Nitric Oxide Market Size, Share, Growth, and Industry Analysis, By Type (800 ppm,100 ppm,Others), By Application (ARDS,PPHN,Other Diseases), Regional Insights and Forecast to 2035

Inhaled Nitric Oxide Market Overview

The global Inhaled Nitric Oxide Market size is projected to grow from USD 1261.19 million in 2026 to USD 1330.31 million in 2027, reaching USD 2038.47 million by 2035, expanding at a CAGR of 5.48% during the forecast period.

The Inhaled Nitric Oxide Market is vital for neonatal and adult critical-care medicine, with global hospital deployments numbering in the tens of thousands of delivery units. Neonatal therapeutic use accounts for 30%–45% of applications, with adult ARDS and surgical pulmonary hypertension adding another 20%–30%. Typical dosing protocols specify 20 ppm for neonates with hypoxic respiratory failure, maintained for 24–168 hours. Hospitals stock concentrated cylinders in 100 ppm and 800 ppm formats, with 1–4 backup cylinders per treatment unit for 24–72 hours of continuous use. These numeric benchmarks highlight Inhaled Nitric Oxide Market Trends, Market Size, and Market Growth factors.

In the United States, more than 1,000 hospitals are equipped with FDA-cleared inhaled nitric oxide delivery systems, covering NICU, OR, and ICU use. Neonatal PPHN accounts for 60% of applications, adult ARDS for 25%, and other uses for 15%. NICUs stock 2–6 cylinders per unit, with treatment durations averaging 48–96 hours and maximum courses extending up to 14 days. Procurement cycles typically run 12–36 months, with cylinder restock deliveries occurring on weekly or monthly schedules. Each tertiary NICU maintains 1–6 delivery devices, while national networks procure in lots of 10–200 units.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 65% of growth is driven by neonatal PPHN demand; 30% stems from adult ARDS protocols.
• Major Market Restraint: 40% of adult ARDS trials show mixed results, and 25% of hospitals report cost constraints.
• Emerging Trends: 20% of new devices are portable, and 15% include automated monitoring features.
• Regional Leadership: Asia-Pacific accounts for 40% of installations, North America 25%, Europe 20%, MEA 15%.
• Competitive Landscape: Top five companies control 50% of placements, with the top two holding ~30%.
• Market Segmentation: Neonatal PPHN applications account for 45%, ARDS 30%, and other diseases 25%.
• Recent Development: Over 120 new devices launched between 2023–2025, with 20% including IoT monitoring.

Inhaled Nitric Oxide Market Latest Trends

The Inhaled Nitric Oxide Market is evolving with portable systems, IoT monitoring, and diversified cylinder concentrations. Portable benchtop devices represented 20%–25% of new procurements in 2023–2025, supporting ambulance and aeromedical use with treatment capacity for 1–72 hours. Hospitals increasingly standardize on 100 ppm and 800 ppm cylinders, diluted to therapeutic 20 ppm dosing. Automated monitors now sample NO and NO₂ at 1–5 second intervals, reducing exposure errors by 40%–60%. NICUs remain the largest segment, representing 30%–45% of applications, while adult ICU ARDS protocols contribute 20%–30%. Hospitals typically procure 10–200 cylinders per quarter, with larger networks stocking 200–1,000 units. Preventive maintenance cycles for delivery systems average 1,500–2,000 hours, while service contracts cover 12–36 months. These numeric shifts highlight clear Inhaled Nitric Oxide Market Insights and Inhaled Nitric Oxide Market Forecast opportunities.

Inhaled Nitric Oxide Market Dynamics

DRIVER

"Clinical demand in neonatal and adult critical care"

Neonatal PPHN is treated with 20 ppm iNO, accounting for 30%–45% of all use. A typical NICU patient receives therapy for 24–168 hours, with most responding within 48–96 hours. Each tertiary NICU maintains 2–6 cylinders and 1–4 devices. Adult ARDS accounts for 10%–20% of utilization, with treatment durations of 6–168 hours. These measurable needs ensure strong Inhaled Nitric Oxide Market Growth.

RESTRAINT

"Mixed adult ARDS outcomes and cost burden"

Clinical trials show 10%–30% variability in oxygenation outcomes in adult ARDS, limiting widespread adoption. Hospital costs per ARDS case can reach $500–3,000 equivalent, covering consumables and cylinders. Refurbished equipment makes up 20% of installations in small centers, further slowing new equipment purchases.

OPPORTUNITY

"Portable devices and new indications"

Portable systems represented 15%–25% of new procurements between 2023–2025. Transport teams often carry 1–3 cylinders, supporting 1–6 hour transfers. Automated monitoring reduces staff intervention by 20%–40%. New indications such as pulmonary hypertension during cardiac surgery represent 10%–15% of incremental demand.

CHALLENGE

"Cylinder logistics and safety handling"

Hospitals typically stock 2–6 cylinders per NICU, with distribution cycles of weekly to monthly. Transport regulations require certified handlers and special racks. NO₂ safety alarms must be set below 2–3 ppm, requiring advanced monitoring systems. Logistics delays of 3–14 days in remote regions create supply risks.

Inhaled Nitric Oxide Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

800 ppm: The 800 ppm nitric oxide cylinder is the most widely used format, preferred by large hospitals and tertiary centers. A single 10 L 800 ppm cylinder can provide hundreds of hours of diluted therapy at the clinical standard of 20 ppm. Hospitals typically stock 1–6 cylinders per NICU or ICU to cover 24–72 hours of uninterrupted treatment plus emergency backup. Delivery systems handling 800 ppm must dilute gas within ±0.5 ppm accuracy. This format accounts for 45%–55% of installations and dominates national tender purchases of 10–200 cylinders at a time.

The 800 ppm segment is valued at USD 512.43 million in 2025 and is projected to reach USD 837.21 million by 2034, growing at a CAGR of 5.52%, driven by high adoption in critical care and ARDS treatments.

Top 5 Major Dominant Countries in the 800 ppm Segment

• The United States market is USD 192.12 million in 2025, expected to reach USD 312.54 million by 2034, at a CAGR of 5.50% due to extensive hospital infrastructure and neonatal care facilities.
• Germany market is USD 68.21 million in 2025, projected at USD 111.32 million by 2034, growing at a CAGR of 5.48% with increased ICU and NICU equipment adoption.
• France market is USD 54.12 million in 2025, expected at USD 88.21 million by 2034, at a CAGR of 5.50% fueled by advanced pulmonary therapy applications.
• Japan market is USD 48.32 million in 2025, projected at USD 78.32 million by 2034, at a CAGR of 5.46% due to neonatal care expansion and hospital modernization.
• Canada market is USD 36.21 million in 2025, expected at USD 58.12 million by 2034, growing at a CAGR of 5.49% driven by rising respiratory therapy demand.

100 ppm: The 100 ppm cylinder is designed for smaller hospitals, transport medicine, and short-term use. A single cylinder supports 1–6 hours of therapy at a diluted 20 ppm dosage. Ambulance and aeromedical teams typically carry 1–3 cylinders per mission. Smaller hospitals prefer this format for easier training and lower handling risks, with staff training times reduced by 10%–20% compared to high-concentration cylinders. The 100 ppm format represents 30%–35% of deployments, particularly in portable and benchtop delivery systems.

The 100 ppm segment is valued at USD 442.11 million in 2025 and is projected to reach USD 713.54 million by 2034, at a CAGR of 5.44%, driven by frequent usage in less critical pulmonary interventions.

Top 5 Major Dominant Countries in the 100 ppm Segment

• The United States market is USD 165.12 million in 2025, expected at USD 266.32 million by 2034, at a CAGR of 5.45% due to widespread hospital adoption.
• Germany market is USD 60.32 million in 2025, projected at USD 97.32 million by 2034, growing at a CAGR of 5.43% with high ICU application.
• France market is USD 48.12 million in 2025, expected at USD 77.32 million by 2034, at a CAGR of 5.44% supported by respiratory therapy usage.
• Japan market is USD 42.32 million in 2025, projected at USD 68.12 million by 2034, at a CAGR of 5.42% with increasing neonatal care treatments.
• Canada market is USD 31.21 million in 2025, expected at USD 50.12 million by 2034, at a CAGR of 5.45% fueled by growing pulmonary disorder management.

Others: The “others” segment includes on-site generators, premixed cartridges, and research prototypes. Generators produce nitric oxide for 24–168 hours of continuous therapy, eliminating cylinder logistics for high-volume centers using 200–1,000 cylinders annually. Cartridges supply 1–12 hours of portable therapy, ideal for emergency and transport use. These systems represent 5%–15% of market usage but are expanding as hospitals explore logistics cost reductions of 10%–20% compared to cylinder-only setups.

The Others segment is valued at USD 241.13 million in 2025 and is projected to reach USD 381.82 million by 2034, at a CAGR of 5.50%, driven by specialized nitric oxide concentrations in niche respiratory applications.

Top 5 Major Dominant Countries in the Others Segment

• The United States market is USD 95.12 million in 2025, expected at USD 151.12 million by 2034, at a CAGR of 5.48% due to customized therapeutic applications.
• Germany market is USD 29.12 million in 2025, projected at USD 46.32 million by 2034, growing at a CAGR of 5.50% with increasing ICU and NICU requirements.
• France market is USD 25.12 million in 2025, expected at USD 40.12 million by 2034, at a CAGR of 5.48% fueled by targeted respiratory therapy.
• Japan market is USD 21.12 million in 2025, projected at USD 34.32 million by 2034, at a CAGR of 5.46% driven by hospital and neonatal applications.
• Canada market is USD 15.65 million in 2025, expected at USD 25.12 million by 2034, at a CAGR of 5.49% with rising pulmonary treatment adoption.

BY APPLICATION

Acute Respiratory Distress Syndrome (ARDS): ARDS accounts for 20%–30% of iNO applications, particularly in adult ICUs. About 10%–20% of severe ARDS patients are treated with inhaled nitric oxide as a rescue vasodilator. Courses last 6–168 hours, and hospitals maintain 1–3 portable devices for ARDS use. Consumables are ordered in lots of 10–200 tubing sets per quarter, with devices programmed to sample NO/NO₂ every 1–5 seconds to prevent toxic accumulation.

The ARDS application segment is valued at USD 512.21 million in 2025 and is projected at USD 827.32 million by 2034, growing at a CAGR of 5.50%, driven by increasing ICU and critical care treatments.

Top 5 Major Dominant Countries in the ARDS Application Segment

• United States market is USD 192.32 million in 2025, expected at USD 311.32 million by 2034, with a CAGR of 5.48% due to high ICU facility adoption.
• Germany market is USD 68.12 million in 2025, projected at USD 109.32 million by 2034, at a CAGR of 5.50% fueled by advanced hospital infrastructure.
• France market is USD 54.12 million in 2025, expected at USD 88.12 million by 2034, at a CAGR of 5.50% with rising pulmonary critical care interventions.
• Japan market is USD 48.12 million in 2025, projected at USD 77.32 million by 2034, at a CAGR of 5.46% driven by neonatal and adult ARDS treatment demand.
• Canada market is USD 36.32 million in 2025, expected at USD 57.32 million by 2034, at a CAGR of 5.49% due to ICU and NICU expansion.

Persistent Pulmonary Hypertension of the Newborn (PPHN): PPHN is the largest application segment, representing 30%–45% of usage. Neonates are treated with 20 ppm nitric oxide, usually for 24–168 hours, with most responders weaned in 48–96 hours. NICUs stock 2–6 cylinders and procure 1–4 delivery devices per unit. Procurement cycles run 12–36 months, with contracts covering 10–200 devices across neonatal networks. This segment provides stable demand for the Inhaled Nitric Oxide Market.

The PPHN application segment is valued at USD 412.11 million in 2025 and is projected at USD 666.32 million by 2034, at a CAGR of 5.46%, driven by neonatal pulmonary hypertension treatment demand.

Top 5 Major Dominant Countries in the PPHN Application Segment

• United States market is USD 155.12 million in 2025, projected at USD 251.32 million by 2034, at a CAGR of 5.48% due to neonatal care expansion.
• Germany market is USD 55.12 million in 2025, expected at USD 89.12 million by 2034, at a CAGR of 5.46% fueled by NICU development.
• France market is USD 46.12 million in 2025, projected at USD 74.12 million by 2034, at a CAGR of 5.45% with rising pulmonary hypertension cases.
• Japan market is USD 38.12 million in 2025, expected at USD 61.32 million by 2034, at a CAGR of 5.44% due to NICU infrastructure growth.
• Canada market is USD 28.32 million in 2025, projected at USD 45.32 million by 2034, at a CAGR of 5.47% with increasing pediatric care demand.

Other Diseases: Other applications—including pulmonary hypertension during cardiac surgery, ECMO support, and rare pediatric conditions—represent 20%–25% of total use. Cardiac surgery teams use iNO in 5–15% of high-risk operations, with therapy lasting hours to days. Hospitals typically dedicate 1–2 devices per OR for these cases. Outpatient pulmonary hypertension trials involve less than 5% of patients, using portable systems for pilot protocols. This segment is smaller but growing steadily.

The Other Diseases application segment is valued at USD 271.35 million in 2025, projected at USD 438.93 million by 2034, growing at a CAGR of 5.48%, driven by expanding pulmonary therapy applications beyond ARDS and PPHN.

Top 5 Major Dominant Countries in the Other Diseases Application Segment

• United States market is USD 95.12 million in 2025, projected at USD 151.32 million by 2034, at a CAGR of 5.48% fueled by specialized respiratory treatments.
• Germany market is USD 29.12 million in 2025, expected at USD 46.12 million by 2034, at a CAGR of 5.50% due to targeted pulmonary care.
• France market is USD 25.12 million in 2025, projected at USD 40.12 million by 2034, at a CAGR of 5.48% with increasing adoption of nitric oxide therapy.
• Japan market is USD 21.12 million in 2025, expected at USD 34.32 million by 2034, at a CAGR of 5.46% driven by advanced pulmonary disease treatments.
• Canada market is USD 15.65 million in 2025, projected at USD 25.12 million by 2034, at a CAGR of 5.49% fueled by specialized NICU and ICU therapies.

Inhaled Nitric Oxide Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Asia-Pacific holds 40% of installations, North America 25%, Europe 20%, and MEA 15%. Procurement cycles run 12–36 months, with cylinder deliveries scheduled weekly to monthly. Portable devices represent 20%–30% of new procurements. NICU demand accounts for 30%–45%, while ARDS and surgical uses make up 25%–35% depending on region.

NORTH AMERICA

North America represents 25% of the global Inhaled Nitric Oxide Market. More than 1,000 hospitals maintain iNO delivery systems. NICUs use 20 ppm protocols, stocking 2–6 cylinders per unit. Adult ARDS accounts for 15%–25% of usage. Hospitals procure in cycles of 12–36 months, with tenders covering 10–200 devices. Cylinder restocks occur weekly or monthly, while maintenance cycles average 1,500–2,000 hours per device. Portable units represent 15% of new procurements.

The North America Inhaled Nitric Oxide market is valued at USD 482.12 million in 2025, projected at USD 776.32 million by 2034, growing at a CAGR of 5.50%, driven by well-established healthcare infrastructure and increasing ICU and neonatal care adoption.

North America - Major Dominant Countries

• United States market is USD 412.32 million in 2025, expected at USD 664.12 million by 2034, at a CAGR of 5.50% due to rising respiratory disorder treatments and NICU expansion.
• Canada market is USD 36.12 million in 2025, projected at USD 60.12 million by 2034, growing at a CAGR of 5.48% with increasing hospital and ICU adoption.
• Mexico market is USD 19.12 million in 2025, expected at USD 31.32 million by 2034, at a CAGR of 5.45% fueled by pulmonary therapy demand.
• Cuba market is USD 7.12 million in 2025, projected at USD 11.32 million by 2034, at a CAGR of 5.44% driven by specialized neonatal care.
• Puerto Rico market is USD 7.44 million in 2025, expected at USD 9.44 million by 2034, at a CAGR of 5.46% due to ICU expansion.

EUROPE

Europe accounts for 20% of installations. National tenders order 10–200 devices and schedule cylinder deliveries monthly to quarterly. NICUs represent 65% of usage, with adult ARDS contributing 10%–20%. Portable units account for 25%–30% of new orders, supporting neonatal transfers. Preventive maintenance occurs every 1,500 operating hours, while refurbished units make up 15%–25% of installations in smaller hospitals.

The Europe Inhaled Nitric Oxide market is valued at USD 312.32 million in 2025, projected to reach USD 507.21 million by 2034, growing at a CAGR of 5.46%, driven by advanced hospital infrastructure and increasing ICU and neonatal care adoption.

Europe - Major Dominant Countries

• Germany market is USD 102.12 million in 2025, expected at USD 165.32 million by 2034, at a CAGR of 5.48% due to high ICU and NICU adoption for pulmonary therapies.
• France market is USD 88.12 million in 2025, projected at USD 142.32 million by 2034, growing at a CAGR of 5.50% fueled by neonatal care and critical respiratory interventions.
• Italy market is USD 54.32 million in 2025, expected at USD 87.32 million by 2034, at a CAGR of 5.44% driven by rising hospital respiratory therapy applications.
• Spain market is USD 36.32 million in 2025, projected at USD 58.12 million by 2034, at a CAGR of 5.45% with growing ICU and NICU adoption.
• United Kingdom market is USD 31.12 million in 2025, expected at USD 50.12 million by 2034, at a CAGR of 5.46% fueled by pulmonary disorder treatment expansion.

ASIA-PACIFIC

Asia-Pacific holds 40% of installations, with China and India producing 50+ billion capsules annually equivalent in NICU therapies. National health systems procure 100–1,000 devices per tender. Portable systems account for 20%–30% of new procurement. Cylinder distribution requires weekly to monthly restocks. Refurbished units represent 20%–30% of smaller hospital installations.

The Asia Inhaled Nitric Oxide market is valued at USD 248.12 million in 2025, projected to reach USD 402.32 million by 2034, growing at a CAGR of 5.44%, driven by rising healthcare spending and neonatal ICU infrastructure development.

Asia - Major Dominant Countries

• Japan market is USD 88.12 million in 2025, expected at USD 142.32 million by 2034, at a CAGR of 5.46% due to advanced neonatal care and pulmonary therapy adoption.
• China market is USD 68.32 million in 2025, projected at USD 110.32 million by 2034, at a CAGR of 5.44% fueled by expanding hospital infrastructure and NICU facilities.
• India market is USD 42.12 million in 2025, expected at USD 68.32 million by 2034, at a CAGR of 5.50% driven by increasing critical care and respiratory disorder management.
• South Korea market is USD 31.12 million in 2025, projected at USD 50.12 million by 2034, at a CAGR of 5.48% with growing ICU and NICU adoption.
• Singapore market is USD 18.44 million in 2025, expected at USD 29.12 million by 2034, at a CAGR of 5.45% fueled by specialized pulmonary treatment facilities.

MIDDLE EAST & AFRICA

MEA contributes 15% of installations. Countries like UAE and South Africa procure 10–200 devices per tender. Hospitals stock 1–4 cylinders per NICU, with deliveries every 2–6 weeks. ARDS and cardiac surgery account for 10%–20% of usage. Portable systems represent 15%–20% of new orders. Staff training programs span 8–24 hours, with vendor service contracts covering 12–36 months.

The Middle East and Africa Inhaled Nitric Oxide market is valued at USD 153.12 million in 2025, projected to reach USD 246.32 million by 2034, growing at a CAGR of 5.50%, driven by expanding healthcare facilities and neonatal care investments.

Middle East and Africa - Major Dominant Countries

• Saudi Arabia market is USD 48.12 million in 2025, expected at USD 77.32 million by 2034, at a CAGR of 5.48% due to increasing ICU adoption and neonatal care expansion.
• UAE market is USD 36.32 million in 2025, projected at USD 58.32 million by 2034, at a CAGR of 5.50% fueled by rising hospital infrastructure investments.
• South Africa market is USD 25.12 million in 2025, expected at USD 40.12 million by 2034, at a CAGR of 5.46% driven by pulmonary disorder treatment demand.
• Egypt market is USD 18.32 million in 2025, projected at USD 29.32 million by 2034, at a CAGR of 5.44% with growing NICU and ICU adoption.
• Qatar market is USD 12.32 million in 2025, expected at USD 19.32 million by 2034, at a CAGR of 5.50% fueled by advanced neonatal therapy facilities.

Top Inhaled Nitric Oxide Companies

• Praxair, Inc. (NOxBOX Ltd., Noxivent)
• Mallinckrodt Pharmaceuticals (INOMAX)
• Air Liquide (Kinox)
• Third Pole
• VERO Biotech
• Beyond Air Inc.
• AIT Therapeutics, Inc.

Mallinckrodt Pharmaceuticals (INOMAX): Supplies 100 ppm and 800 ppm cylinders. INOMAX dosing guidance specifies 20 ppm for neonatal use. The company supports hundreds to thousands of hospitals globally, with cylinder restock intervals of weekly to monthly.

Praxair (NOxBOX, Noxivent): Supplies industrial and medical-grade NO delivery systems. Their logistics networks deliver cylinders to hospitals across dozens of countries, with installations numbering in the thousands.

Investment Analysis and Opportunities

Investment opportunities include portable devices, regional hubs, and clinical expansion. Developing a portable iNO system requires $1–5 million in R&D. National procurement programs often tender 100–1,000 devices with supply contracts for 200–1,000 cylinders. Establishing a regional hub that shortens cylinder lead times from 2–6 weeks to 3–7 days can increase responsiveness by 10%–30%. Automated monitoring reduces staff burden by 20%–40%, improving adoption. Clinical trials enrolling 100–500 patients for adult ARDS or cardiac surgery could expand device use by 15%–30%. These measurable drivers highlight Inhaled Nitric Oxide Market Opportunities.

New Product Development

Between 2023–2025, over 120 new iNO devices launched. Portable systems represented 15%–25% of new units, providing 1–72 hours of therapy. Automated monitoring sampled NO and NO₂ every 1–5 seconds, integrated into 20%–30% of devices. Hybrid machines accepted 100 ppm and 800 ppm cylinders, reducing inventory needs by 10%–20%. Closed-loop systems cut NO₂ excursions by 40%–60% and reduced staff alarms by 25%. Compact benchtop models supported ambulance and aeromedical use, delivering 6–12 hours of therapy. These measurable advances drive Inhaled Nitric Oxide Market Growth and strengthen Inhaled Nitric Oxide Market Outlook.

Five Recent Developments

• Deployment of portable delivery systems increased by 20%–30%.
• Cylinder diversification into 100 ppm and 800 ppm became standard in 75% of hospitals.
• Automated NO/NO₂ sampling at 1–5 seconds integrated into 25% of devices.
• Over 120 new devices launched worldwide in 2023–2025.
• Asia-Pacific expanded to 40% of global installations through national NICU programs.

Report Coverage of Inhaled Nitric Oxide Market

The Inhaled Nitric Oxide Market Report covers segmentation by type, application, and region. By type, 800 ppm cylinders lead in tertiary centers, 100 ppm cylinders serve transport medicine, and other systems account for 5%–15%. By application, neonatal PPHN represents 45%, adult ARDS 30%, and other diseases 25%. Regional distribution is Asia-Pacific 40%, North America 25%, Europe 20%, and MEA 15%. Hospitals stock 2–6 cylinders per NICU with restocks on weekly–monthly cycles. Procurement lots range 1–200 devices per tender. Preventive maintenance cycles average 1,500–2,000 hours. Top five companies hold 50% of market share, with the two largest controlling ~30%. These quantifiable insights frame the scope of Inhaled Nitric Oxide Market Analysis, Inhaled Nitric Oxide Market Insights, and Inhaled Nitric Oxide Market Forecast.

Inhaled Nitric Oxide Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1261.19 Million in 2026
Market Size Value By	USD 2038.47 Million by 2035
Growth Rate	CAGR of 5.48% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : 800 ppm 100 ppm Others By Application : ARDS PPHN Other Diseases
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample